New Delhi, Nov 26 (IANS) Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable access are the major barriers, according to a report on Tuesday.
Biologic therapy, also known as immunotherapy, is a type of treatment that uses substances derived from living organisms to treat disease.
The report by GlobalData, a data and analytics company, showed that the new Biologics target specific inflammatory pathways, shifting care from symptom control to potential remission.
Biologic treatments like dupilumab interleukin-4 receptor alpha and tezepelumab (anti-thymic stromal lymphopoietin (TSLP)) show potential for wider application. They also offer benefits to patients with various inflammatory profiles.
As per real-world evidence, these therapies have proved their efficacy across diverse patient profiles, including those with complex asthma cases.
However, the report cited barriers such as cost and accessibility. It stressed the urgent need for equitable healthcare solutions to ensure the widespread adoption of these transformative treatments.
“Biologics have fundamentally changed our approach to severe asthma by enabling targeted, personalised treatment, but expanding access is crucial to realising their full potential,” Sravani Meka, Senior Pharmaceutical Analyst at GlobalData.
“The long-term impact of these therapies could shift asthma management from simply controlling symptoms to achieving remission, like advances seen in fields like rheumatoid arthritis,” Meka added.
While biologics have shown great promise, barriers such as cost, access, and insurance coverage limit their availability, particularly in underserved communities.
This is further complicated by environmental and social factors. Many patients in high-risk areas are disproportionately exposed to pollutants that worsen symptoms.
“Tezepelumab’s broad efficacy, even for patients with low eosinophil (a type of white blood cell that helps fight infections) counts, highlights the potential of biologics to address asthma across diverse profiles and patient demographics,” Meka said.
Systemic changes to improve healthcare equity and accessibility are crucial even as efforts to expand access to biologics in severe asthma treatment are underway,
Meka called for “sustained attention to cost and accessibility issues”. She noted that this will ensure that biologics are available to all needy patients.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
